Hydroxychloroquine intranasal - APT Pharmaceuticals

Drug Profile

Hydroxychloroquine intranasal - APT Pharmaceuticals

Alternative Names: APT-004; APT-005; APT-006

Latest Information Update: 31 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator APT Pharmaceuticals Inc
  • Class Antimalarials; Antivirals; Chlorobenzenes; Disease-modifying antirheumatics; Ethanolamines; Quinolines; Small molecules
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Nasal polyps; Rhinovirus infections; Seasonal allergic rhinitis

Most Recent Events

  • 31 Jul 2013 No development reported - Preclinical for Nasal polyps in USA (Intranasal)
  • 31 Jul 2013 No development reported - Preclinical for Rhinovirus infections in USA (Intranasal)
  • 31 Jul 2013 No development reported - Preclinical for Seasonal allergic rhinitis in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top